Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912 Research Letter

  

Authors:	Shanafelt, T. D.; Wang, X. V.; Hanson, C. A.; Paietta, E.; O’Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; Barr, P. M.; Cashen, A. F.; Mato, A. R.; Singh, A. K.; Mullane, M. P.; Little, R. F.; Erba, H.; Stone, R. M.; Litzow, M.; Tallman, M.; Kay, N. E.
Title:	Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Keywords:	adult; controlled study; middle aged; unclassified drug; gene mutation; major clinical study; overall survival; fludarabine; drug tolerability; rituximab; flow cytometry; follow up; progression free survival; randomized controlled trial; cohort analysis; cyclophosphamide; monoclonal antibody; in situ hybridization; fluorescence in situ hybridization; medical education; patient compliance; toxicity testing; disease control; chronic lymphatic leukemia; disease exacerbation; cost benefit analysis; high throughput sequencing; ibrutinib; human; article; bruton tyrosine kinase inhibitor; e1912
Journal Title:	Blood Advances
Volume:	9
Issue:	1
ISSN:	2473-9529
Publisher:	American Society of Hematology
Date Published:	2025-01-14
Start Page:	224
End Page:	228
Language:	English
DOI:	10.1182/bloodadvances.2024013474
PUBMED:	39163612
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85215292684&doi=10.1182%2fbloodadvances.2024013474&partnerID=40&md5=6e4857a60e672ae8c862ef256cd5e6f5
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/222130